October 2025 Journal Review

Prepared By
Mafalda Cardoso, MSc DVM MRCVS
Prognostic Impact of Mast Cell Infiltration Detected by Flow Cytometry on Excised Sentinel Lymph Nodes in Dogs With Newly Diagnosed Mast Cell Tumours
Carmit Chalfon, Silvia Sabattini, Fulvio Riondato, Giulia Iamone, Andrea Renzi, Luca Ciammaichella, Erica Ilaria Ferraris, Kevin Pascal Spindler, Laura Marconato
Veterinary and Comparative Oncology, 2025; Vol 0: pp. 1–13 https://onlinelibrary.wiley.com/doi/epdf/10.1111/vco.70018
Background
Lymph node metastasis is a key negative prognostic factor in canine mast cell tumours (MCTs), affecting treatment decisions and survival outcomes. While fine-needle aspiration cytology is commonly used for staging, it has a notable false-negative rate. Flow cytometry (FC) has emerged as a minimally invasive technique capable of accurately identifying and quantifying mast cells in lymph nodes. However, the prognostic relevance of different levels of nodal infiltration detected by FC remains unclear.
Study Design
This tri-institutional prospective study aimed to evaluate the prognostic relevance of previously reported FC cut-off values for mast cell percentages in sentinel lymph nodes (SLNs) in dogs with cutaneous or subcutaneous MCTs. The primary objective was to assess their association with time to progression (TTP) and tumour-specific survival (TSS), while a secondary aim was to identify new cut-off values with prognostic significance for future in vivo validation
Animals
64 dogs with newly diagnosed, untreated, single cutaneous or subcutaneous MCTs were included. All dogs were scheduled to undergo primary tumour excision and sentinel lymphadenectomy. Eligibility criteria required complete clinical staging, including SLN mapping via radiographic or computed tomography lymphography, and SLN evaluation by cytology and FC.
Methods
At the time of surgery, 2–5 fine-needle aspirates were performed ex vivo on excised SLNs. Aspirated material was transferred into RPMI medium enriched with sodium azide and foetal calf serum for FC analysis. One to two smears per SLN were prepared for cytologic evaluation, and SLNs were fixed in 10% neutral-buffered formalin for histopathology. Cytologic assessment classified SLNs according to the system described by Krick as normal/reactive lymph node, possible metastasis, probable metastasis, or certain metastasis. Histopathologic assessment followed the classification system described by Weishaar (HN0–HN3). FC analysis was conducted using antibodies against CD117, IgE, CD5, and CD21. Mast cells were identified as CD117⁺ IgE⁺ CD5⁻ CD21⁻ and quantified as a percentage of intact cells.
Results
A total of 117 SLNs were identified, with a median of 1 SLN per dog (range: 1–7). Clinically, 48 dogs (75%) had normal-sized SLNs, and 16 (25%) had enlarged SLNs, including 2 that were firm and fixed. Thirteen dogs (20.3%) received adjuvant vinblastine: 8 had low-grade MCT with at least one HN3 SLN, 4 had high-grade MCT with HN3 SLN, and 1 had high-grade MCT with HN2 SLN. Univariable analysis showed that tumour ulceration, high-grade MCT, HN3 nodal status, and SLN mast cell infiltration >1.1% and >4% were significantly associated with increased risk of tumour progression. Tumour ulceration, diameter ≥3 cm, and high-grade MCT were linked to increased risk of tumour-related death. Shorter TSS was associated with HN3 SLNs and SLN mast cell infiltration >4%. ROC analysis identified 16% SLN infiltration as the optimal cut-off to predict tumour-related death.
Important Findings
SLN mast cell infiltration thresholds of >1.1% and >4% were significantly associated with tumour progression, with dogs above these levels showing a markedly higher likelihood of disease progression. These thresholds support risk stratification into low (<1.1%), intermediate (1.1–4%), and high-risk (>4%) groups, aiding prognosis. No tumour-related deaths occurred in dogs without HN3 SLNs or with SLN infiltration <4%, indicating a clear separation in outcomes. Both HN3 SLN presence and SLN infiltration >4% were significantly associated with shorter TSS. A SLN infiltration cut-off of 16% predicted tumour-related death with 100% sensitivity and specificity.
Study Limitations
Despite a relatively large sample size, the low number of events limited statistical power. This may be due to the predominance of low-grade MCTs, complete surgical margins, consistent SLN removal, and adjuvant chemotherapy in high-risk cases. These factors likely contributed to the favourable outcomes observed. The optimal SLN infiltration cut-off for predicting tumour-related death may be overestimated due to the small number of deaths, making survival analyses exploratory and requiring validation in larger cohorts. FC samples were obtained ex vivo, which may differ from in vivo results, especially in small or deep LNs. Two SLN mapping techniques were used based on anatomy and cost, introducing variability but reflecting real-world practice. Finally, the FC markers used cannot distinguish neoplastic from non-neoplastic mast cells.
Journal Reviewer Comments
This study highlights FC as a promising tool for staging and risk stratification in canine MCTs, particularly through SLN mast cell infiltration thresholds that help predict prognosis. While FC is minimally invasive and provides timely results, its effectiveness depends on sample quality and timely processing. These factors underscore the continued importance of lymphadenectomy and histologic evaluation for definitive staging. Further studies are needed to validate FC-based thresholds in larger cohorts, explore its utility in in vivo sampling, and better define the immunophenotype of canine mast cells to improve differentiation between neoplastic and non-neoplastic populations.
0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *

Copyright © 2026 World Veterinary Oncology Consortium